Abstract
The polypill concept for atherosclerosis is based on the notion that a single pill
containing multiple products that attack frequently encountered risk factors will
provide important advantages as a preventive strategy, particularly in the developing
world. Potential benefits include improved efficacy and greater compliance because
of simplicity and reduced costs. Here, we briefly review the rationale for the polypill
and the evidence supporting its value. We consider the polypill to be a major advance
in combat against cardiovascular disease, with enormous benefits to global health
to be expected from its use.
Résumé
Dans un contexte d'athérosclérose, le concept de polypill est basé sur la notion qu’une
seule pilule, composée de multiples agents pharmacologiques, puisse cibler les facteurs
de risques les plus fréquemment rencontrés. Cette approche thérapeutique apportera
d’importants avantages comme stratégie préventive, particulièrement dans un monde
en développement. Les bénéfices potentiels incluent des coûts réduits, une meilleure
efficacité et une observance accrue de par sa simplicité d’utilisation. Dans cet article,
nous discutons du concept de polypill ainsi que les preuves supportant sa validité
clinique. Nous considérons que le polypill est une avancée majeure dans la lutte contre
les maladies cardiovasculaires et aura d’énormes bienfaits sur la santé mondiale.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A strategy to reduce cardiovascular disease by more than 80%.BMJ. 2003; 326: 1419
- Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects.J Intern Med. 1999; 245: 163-174
- Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification.Hypertension. 2000; 35: 539-543
- Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).J Clin Hypertens (Greenwich). 2008; 10: 751-760
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet. 2003; 361: 1149-1158
- Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.Congest Heart Fail. 2003; 9: 324-332
- A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.Hypertension. 2009; 53: 646-653
- Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice.Hypertension. 2011; 58: 566-572
- Improved blood pressure control associated with a large-scale hypertension program.JAMA. 2013; 310: 699-705
- A single fixed-dose combination for all patients is bad medicine.Can J Cardiol. 2014; 30: 513-516
- Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.JAMA. 2013; 310: 918-929
- Evolution of the polypill concept and ongoing clinical trials.Can J Cardiol. 2014; 30: 520-526
Article info
Publication history
Published online: March 17, 2014
Accepted:
March 12,
2014
Received:
March 12,
2014
Footnotes
See article by Spence, pages 513-516 of this issue.
See page 518 for disclosure information.
Identification
Copyright
© 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
